43200-88-0 Usage
Description
6-(5-CHLORO-PYRIDIN-2-YL)-7-PHENOXYCARBONYLOXY-6,7-DIHYDRO-PYRROLO3,4-BPYRAZIN-5-ONE is a chemical compound with a complex molecular structure that holds potential in the pharmaceutical industry due to its tranquilizing and anticonvulsant properties.
Uses
Used in Pharmaceutical Applications:
6-(5-CHLORO-PYRIDIN-2-YL)-7-PHENOXYCARBONYLOXY-6,7-DIHYDRO-PYRROLO3,4-BPYRAZIN-5-ONE is used as a tranquilizer and anticonvulsant for its ability to provide calming effects and control seizures, making it a valuable compound for the treatment of anxiety and epilepsy.
Used in the Mental Health Industry:
In the mental health industry, 6-(5-CHLORO-PYRIDIN-2-YL)-7-PHENOXYCARBONYLOXY-6,7-DIHYDRO-PYRROLO3,4-BPYRAZIN-5-ONE is used as a therapeutic agent for managing anxiety disorders and other conditions that require tranquilizing effects to improve the patient's quality of life.
Used in the Neurology Industry:
6-(5-CHLORO-PYRIDIN-2-YL)-7-PHENOXYCARBONYLOXY-6,7-DIHYDRO-PYRROLO3,4-BPYRAZIN-5-ONE is used as an anticonvulsant in the neurology industry to help control and prevent seizures in patients suffering from epilepsy and other seizure disorders. Its effectiveness in managing these conditions can lead to better patient outcomes and improved daily functioning.
Check Digit Verification of cas no
The CAS Registry Mumber 43200-88-0 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 4,3,2,0 and 0 respectively; the second part has 2 digits, 8 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 43200-88:
(7*4)+(6*3)+(5*2)+(4*0)+(3*0)+(2*8)+(1*8)=80
80 % 10 = 0
So 43200-88-0 is a valid CAS Registry Number.
InChI:InChI=1/C18H11ClN4O4/c19-11-6-7-13(22-10-11)23-16(24)14-15(21-9-8-20-14)17(23)27-18(25)26-12-4-2-1-3-5-12/h1-10,17H
43200-88-0Relevant articles and documents
COMPOSITIONS AND METHODS FOR REDUCING TACTILE DYSFUNCTION, ANXIETY, AND SOCIAL IMPAIRMENT
-
Page/Page column 67-68, (2019/12/25)
The present invention features novel peripherally-restricted non-benzodiazipene analogs with reduced blood brain barrier permeability and methods of use thereof for reducing tactile dysfunction, social impairment, and anxiety in a subject diagnosed with A
A NEW METHOD FOR PREPARATION OF ZOPICLONE AND ITS POLYMORPHS
-
Page/Page column 12, (2009/09/04)
A process for the preparation of crystalline Zopiclone comprising i) suspending zopiclone in a mixture of acetonitrile and diisopropyl ether, filtering and drying the resulting solid; ii) dissolving the solid in step i) in N,N-dimethylformamide to get a clear solution; iii) heating and then precipitating solid; iv) filtering and drying the solid to get crystalline zopiclone. Crystalline zopiclone Form C. Crystalline Zopiclone Form D characterized by an X-ray powder diffraction pattern that comprises peaks with 2theta values of at least 14.8, 19.8, 21.3, 27.3 °2θ ± 0.2 °2θ. A process for preparation of crystalline Zopiclone Form D comprising dissolving Zopiclone in N,N-dimethylformamide and filtering; washing clear filtrate with an alkali solution; separating and concentrating the organic layer, adding isopropyl alcohol thereto and concentrating further to get a slurry; filtering the slurry and drying the resultant solid to get crystalline Zopiclone form D. Pharmaceutical composition comprising crystalline forms of Zopiclone.